Morgan Stanley
CSTL icon

Morgan Stanley’s Castle Biosciences CSTL Stock Holding History

Morgan Stanley’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.86M Sell
329,684
-99,250
-23% -$2.21M ﹤0.01% 3894
2026
Q1 		$10.5M Buy
428,934
+225,357
+111% +$7.38M ﹤0.01% 3530
2025
Q4 		$7.92M Sell
203,577
-66,054
-24% -$2.13M ﹤0.01% 3810
2025
Q3 		$6.14M Buy
269,631
+102,043
+61% +$2.07M ﹤0.01% 3986
2025
Q2 		$3.42M Sell
167,588
-44,205
-21% -$818K ﹤0.01% 4357
2025
Q1 		$4.24M Sell
211,793
-94,884
-31% -$2.35M ﹤0.01% 4066
2024
Q4 		$8.17M Sell
306,677
-90,242
-23% -$2.75M ﹤0.01% 3569
2024
Q3 		$11.3M Buy
396,919
+147,539
+59% +$3.76M ﹤0.01% 3336
2024
Q2 		$5.43M Sell
249,380
-401,331
-62% -$8.94M ﹤0.01% 3808
2024
Q1 		$14.4M Buy
650,711
+172,676
+36% +$3.76M ﹤0.01% 3023
2023
Q4 		$10.3M Buy
478,035
+439,389
+1,137% +$7.73M ﹤0.01% 3320
2023
Q3 		$653K Sell
38,646
-66,134
-63% -$1.16M ﹤0.01% 5039
2023
Q2 		$1.44M Buy
104,780
+15,916
+18% +$323K ﹤0.01% 4616
2023
Q1 		$2.02M Buy
88,864
+30,546
+52% +$746K ﹤0.01% 4459
2022
Q4 		$1.37M Sell
58,318
-137,484
-70% -$3.19M ﹤0.01% 4686
2022
Q3 		$5.11M Buy
195,802
+86,863
+80% +$2.44M ﹤0.01% 3672
2022
Q2 		$2.39M Buy
108,939
+81,797
+301% +$1.9M ﹤0.01% 4391
2022
Q1 		$1.22M Sell
27,142
-15,757
-37% -$651K ﹤0.01% 4864
2021
Q4 		$1.84M Sell
42,899
-26,923
-39% -$1.41M ﹤0.01% 4643
2021
Q3 		$4.64M Buy
69,822
+22,343
+47% +$1.57M ﹤0.01% 3797
2021
Q2 		$3.48M Sell
47,479
-88,939
-65% -$5.87M ﹤0.01% 4151
2021
Q1 		$9.34M Buy
136,418
+60,086
+79% +$4.52M ﹤0.01% 2728
2020
Q4 		$5.13M Buy
76,332
+23,052
+43% +$1.25M ﹤0.01% 3231
2020
Q3 		$2.74M Sell
53,280
-262,236
-83% -$11.7M ﹤0.01% 3364
2020
Q2 		$11.9M Buy
315,516
+314,133
+22,714% +$10.7M ﹤0.01% 1807
2020
Q1 		$41K Sell
1,383
-14,760
-91% -$445K ﹤0.01% 5545
2019
Q4 		$555K Buy
16,143
+12,689
+367% +$310K ﹤0.01% 4870
2019
Q3 		$63K Buy
+3,454
New +$76.6K ﹤0.01% 5613

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's CSTL Position: Q2 2026 in Review

Morgan Stanley reduced its Castle Biosciences (CSTL) stake by 23% in Q2 2026, selling an estimated $2.21M and leaving 329,684 shares worth $7.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3894.

Morgan Stanley first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $14.4M in Q1 2024. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Morgan Stanley held 329,684 shares of Castle Biosciences worth $7.86M as of Q2 2026.
  • Morgan Stanley sold 99,250 Castle Biosciences shares in Q2 2026, an estimated $2.21M.
  • Castle Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3894 holding.
  • Morgan Stanley first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Morgan Stanley's Castle Biosciences position peaked at $14.4M in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.